Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Alpha Synuclein Drugs Development Market Report Overview
Alpha-synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
The Alpha Synuclein pipeline drugs market research report provides comprehensive information on the Alpha Synuclein therapeutics under development, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in Alpha Synuclein drug development and features dormant and discontinued projects.
Alpha Synuclein Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Alpha Synuclein pipeline drugs market are intravenous, oral, intrathecal, nasal, and subcutaneous. Oral accounted for the highest Alpha Synuclein drugs in development in terms of RoA.
Alpha Synuclein Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Alpha Synuclein pipeline drugs market, download a free report sample
Alpha Synuclein Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Alpha Synuclein pipeline drugs market are small molecule, monoclonal antibody, gene therapy, fusion protein, antibody, antisense RNAi oligonucleotide, conjugate vaccine, subunit vaccine, antisense oligonucleotide, synthetic peptide, aptamer, DNA vaccine, oligonucleotide, recombinant peptide, and others. Small molecule leads the Alpha Synuclein pipeline drugs market in terms of molecule types.
Alpha Synuclein Pipeline Drugs Market Analysis, by Molecule Type
For more molecule-type insights into the Alpha Synuclein pipeline drugs market, download a free report sample
Alpha Synuclein Pipeline Drugs Market – Competitive Landscape
A number of companies are involved in the development of Alpha Synuclein drugs. Some of these include Alterity Therapeutics Ltd, AC Immune SA, Annovis Bio Inc, Denali Therapeutics Inc, Genmab AS, Proclara Biosciences Inc and Teva Pharmaceutical Industries Ltd among others. AC Immune SA had the most number of Alpha Synuclein drugs under development in 2022
To know more about leading Alpha Synuclein pipeline drugs market players, download a free report sample
Alpha Synuclein Drugs Market Report Overview
| Key Mechanisms of Action | Alpha Synuclein Inhibitor |
| Key Routes of Administration | Intravenous, Oral, Intrathecal, Nasal, and Subcutaneous |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Gene Therapy, Fusion Protein, Antibody, Antisense RNAi Oligonucleotide, Conjugate Vaccine, Subunit Vaccine, Antisense Oligonucleotide, Synthetic Peptide, Aptamer, DNA Vaccine, Oligonucleotide, Recombinant Peptide, and Others |
| Key Companies | Alterity Therapeutics Ltd, AC Immune SA, Annovis Bio Inc, Denali Therapeutics Inc, Genmab AS, Proclara Biosciences Inc, and Teva Pharmaceutical Industries Ltd. |
Scope
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
AC Immune SA
Alterity Therapeutics Ltd
Annovis Bio Inc
Aprinoia Therapeutics Inc
Arvinas Inc
AstraZeneca Plc
AUM LifeTech Inc
BioArctic AB
Chimerna Therapeutics Inc
DegenRx BV
Denali Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Enterin Inc
Fulcrum Therapeutics Inc
Genmab AS
ICB International Inc
Ionis Pharmaceuticals Inc
ND Biosciences SA
Neuramedy Co Ltd
Neurimmune Holding AG
Neuropore Therapies Inc
nLife Therapeutics SL
Nuravax Inc
Prazer Therapeutics
Priavoid GmbH
Primary Peptides Inc
Proclara Biosciences Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
ResQ Biotech
Seelos Therapeutics, Inc.
Selonterra Inc
Shape Therapeutics Inc
Synapss Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Treventis Corp
UCB SA
UniQure NV
Vaxxinity Inc
Wren Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key routes of administration in the Alpha Synuclein pipeline drugs market?
The key routes of administration in the Alpha Synuclein pipeline drugs market are intravenous, oral, intrathecal, nasal, and subcutaneous.
-
What are the key molecule types in the Alpha Synuclein pipeline drugs market?
The molecule types in the Alpha Synuclein drugs market are small molecule, monoclonal antibody, gene therapy, fusion protein, antibody, antisense RNAi oligonucleotide, conjugate vaccine, subunit vaccine, antisense oligonucleotide, synthetic peptide, aptamer, DNA vaccine, oligonucleotide, recombinant peptide, and others.
-
Which are the leading companies in the Alpha Synuclein drugs market?
Some of the leading companies in the Alpha Synuclein pipeline drugs market are Alterity Therapeutics Ltd, AC Immune SA, Annovis Bio Inc, Denali Therapeutics Inc, Genmab AS, Proclara Biosciences Inc, and Teva Pharmaceutical Industries Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports